Suicide and non-fatal suicide attempts among persons with depression in the population of Denmark

Depression increases the risk of suicide death and non-fatal suicide attempt. Between 2 - 6% of persons with depression will die by suicide1 and 25 - 31% of persons with depression will make a non-fatal suicide attempt during their lifetime.2,3 Despite the strong association between depression and suicidal behavior, the vast majority of persons with depression will not engage in suicidal behavior, making it difficult to accurately predict who is at risk for suicide and non-fatal suicide attempt. Identifying high risk persons who should be connected to suicide prevention interventions is an important public health goal. Furthermore, depression often co-occurs with other mental disorders, which may exert an interactive influence on the risk of suicide and suicide attempt. Understanding the joint influence of depression and other mental disorders on suicide outcomes may inform prevention strategies. The goals of this dissertation were to predict suicide and non-fatal suicide attempt among persons with depression and to quantify the causal joint effect of depression and comorbid psychiatric disorders on suicide and suicide attempt. For all three studies, we used data from Danish registries, which routinely collect high-quality data in a setting of universal health care with long-term follow-up and registration of most health and life events.4 In Study 1, we predicted suicide deaths among men and women diagnosed with depression using a case-cohort design (n = 14,737). Approximately 800 predictors were included in the machine learning models (classification trees and random forests), spanning demographic characteristics, income, employment, immigrant status, citizenship, family suicidal history (parent or spouse), previous suicide attempts, mental disorders, physical health disorders, surgeries, prescription drugs, and psychotherapy. In depressed men, we found interactions between hypnotics and sedatives, analgesics and antipyretics, and previous poisonings that were associated with a high risk of suicide. In depressed women, there were interactions between poisoning and anxiolytics and between anxiolytics and hypnotics and sedatives that were associated with suicide risk. The variables in the random forests that contributed the most to prediction accuracy in depressed men were previous poisoning diagnoses and prescriptions of hypnotics and sedatives and anxiolytics. In depressed women, the most important predictors of suicide were receipt of state pension, prescriptions for psychiatric medications (anxiolytics and antipsychotics) and diagnoses of poisoning, alcohol related disorders, and reaction to severe stress and adjustment disorders. Prescriptions of analgesics and antipyretics (e.g., acetaminophen) and antithrombotic agents (e.g., aspirin) emerged as important predictors for both depressed men and women. Study 2 predicted non-fatal suicide attempts among men and women diagnosed with depression using a case-cohort design (n = 17,995). Among depressed men, there was a high risk of suicide attempt among those who received a state pension and were diagnosed with toxic effects of substances. There was also an interaction between reaction to severe stress and adjustment disorder and not receiving psychological help that was associated with suicide attempt risk among depressed men. In depressed women, suicide attempt risk was high in those who were prescribed antipsychotics, diagnosed with specific personality disorders, did not have a poisoning diagnosis, and were not receiving a state pension. For both men and women, the random forest results showed that the strongest contributors to prediction accuracy of suicide attempts were poisonings, alcohol related disorders, reaction to severe stress and adjustment disorders, drugs used to treat psychiatric disorders (e.g., drugs used in addictive disorders, anxiolytics, hypnotics and sedatives), anti-inflammatory medications, receipt of state pension, and remaining single. Study 3 examined the joint effect of depression and other mental disorders on suicide and non-fatal suicide attempts using a case-cohort design (suicide death analysis n = 279,286; suicide attempt analysis n = 288,157). We examined pairwise combinations of depression with: 1) organic disorders, 2) substance use disorders, 3) schizophrenia, 4) bipolar disorder, 5) neurotic disorders, 6) eating disorders, 7) personality disorders, 8) intellectual disabilities, 9) developmental disorders, and 10) behavioral disorders. We fit sex-stratified joint marginal structural Cox models to account for time-varying confounding. We observed large hazard ratios for the joint effect of depression and comorbid mental disorders on suicide and suicide attempts, the effect of depression in the absence of comorbid mental disorders, and for the effect of comorbid mental disorders in the absence of depression. We observed positive and negative interdependence between different combinations of depression and comorbid mental disorders on the rate of suicide and suicide attempt, with variation by sex. Overall, depression and comorbid mental disorders are harmful exposures, both independently and jointly. All of the studies in this dissertation highlight the important role of interactions between risk factors in suicidal behavior among persons with depression. Depression is one of the most commonly assessed risk factors for suicide,5,6 and our findings underscore the value of considering additional risk factors such as other psychiatric disorders, psychiatric medications, and social factors in combination with depression. The results of this dissertation may help inform potential risk identification strategies which may facilitate the targeting of suicide prevention interventions to those most vulnerable

Associations between adjustment disorder and hospital-based infections in the Danish population.

OBJECTIVE:There is some evidence that posttraumatic stress disorder (PTSD) is associated with increased risk of infections, and it is unknown whether adjustment disorder is as well. We assessed the association between adjustment disorder and subsequent infections, and assessed additive interaction with sex. METHODS:The study population included a nationwide cohort of all Danish-born residents of Denmark diagnosed with adjustment disorder between 1995 and 2011, and an age- and sex-matched general population comparison cohort. We compared rates of infections requiring inpatient or outpatient hospitalization in the two cohorts. We fit Cox proportional hazards models to compute adjusted hazard ratios (aHR) for the associations between adjustment disorder and 32 types of infections, and calculated interaction contrasts to assess interaction between adjustment disorder and sex. RESULTS:Adjustment disorder was associated with increased rates of infections overall (n = 19,838 infections, aHR = 1.8, 95% confidence interval = 1.8. 1.9), and increased rates of each individual infection type (aHRs for 30 infections ranged from 1.5 to 2.3), adjusting for baseline psychiatric and somatic comorbidities and marital status. For many infection types (e.g., skin infections, pneumonia), interaction contrasts indicated rate differences were greater among men than women, while for two (urinary tract infections and sexually transmitted infections), rate differences were greater for women. CONCLUSIONS:These findings are consistent with studies examining the relationship between psychological stress and infections, and between PTSD and infections. They may be explained by a combination of the triggering of unhealthy behaviors as well as immune responses to stress

Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge

Epstein-Barr virus (EBV) is a human lymphocryptovirus that is associated with several malignancies. Elevated EBV DNA in the blood is observed in transplant recipients prior to, and at the time of post-transplant lymphoproliferative disease; thus, a vaccine that either prevents EBV infection or lowers the viral load might reduce certain EBV malignancies. Two major approaches have been suggested for an EBV vaccine- immunization with either EBV glycoprotein 350 (gp350) or EBV latency proteins (e.g. EBV nuclear antigens [EBNAs]). No comparative trials, however, have been performed. Rhesus lymphocryptovirus (LCV) encodes a homolog for each gene in EBV and infection of monkeys reproduces the clinical, immunologic, and virologic features of both acute and latent EBV infection. We vaccinated rhesus monkeys at 0, 4 and 12 weeks with (a) soluble rhesus LCV gp350, (b) virus-like replicon particles (VRPs) expressing rhesus LCV gp350, (c) VRPs expressing rhesus LCV gp350, EBNA-3A, and EBNA-3B, or (d) PBS. Animals vaccinated with soluble gp350 produced higher levels of antibody to the glycoprotein than those vaccinated with VRPs expressing gp350. Animals vaccinated with VRPs expressing EBNA-3A and EBNA-3B developed LCV-specific CD4 and CD8 T cell immunity to these proteins, while VRPs expressing gp350 did not induce detectable T cell immunity to gp350. After challenge with rhesus LCV, animals vaccinated with soluble rhesus LCV gp350 had the best level of protection against infection based on seroconversion, viral DNA, and viral RNA in the blood after challenge. Surprisingly, animals vaccinated with gp350 that became infected had the lowest LCV DNA loads in the blood at 23 months after challenge. These studies indicate that gp350 is critical for both protection against infection with rhesus LCV and for reducing the viral load in animals that become infected after challenge. Our results suggest that additional trials with soluble EBV gp350 alone, or in combination with other EBV proteins, should be considered to reduce EBV infection or virus-associated malignancies in humans

Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms

Cancer stem cells (CSCs) possess high tumor-initiating capacity and have been reported to be resistant to therapeutics. Vice versa, therapy-resistant cancer cells seem to manifest CSC phenotypes and properties. It has been generally assumed that drug-resistant cancer cells may all be CSCs although the generality of this assumption is unknown. Here, we chronically treated Du145 prostate cancer cells with etoposide, paclitaxel and some experimental drugs (i.e., staurosporine and 2 paclitaxel analogs), which led to populations of drug-tolerant cells (DTCs). Surprisingly, these DTCs, when implanted either subcutaneously or orthotopically into NOD/SCID mice, exhibited much reduced tumorigenicity or were even non-tumorigenic. Drug-tolerant DLD1 colon cancer cells selected by a similar chronic selection protocol also displayed reduced tumorigenicity whereas drug-tolerant UC14 bladder cancer cells demonstrated either increased or decreased tumor-regenerating capacity. Drug-tolerant Du145 cells demonstrated low proliferative and clonogenic potential and were virtually devoid of CD44+ cells. Prospective knockdown of CD44 in Du145 cells inhibited cell proliferation and tumor regeneration, whereas restoration of CD44 expression in drug-tolerant Du145 cells increased cell proliferation and partially increased tumorigenicity. Interestingly, drug-tolerant Du145 cells showed both increases and decreases in many “stemness” genes. Finally, evidence was provided that chronic drug exposure generated DTCs via epigenetic mechanisms involving molecules such as CD44 and KDM5A. Our results thus reveal that 1) not all DTCs are necessarily CSCs; 2) conventional chemotherapeutic drugs such as taxol and etoposide may directly target CD44+ tumor-initiating cells; and 3) DTCs generated via chronic drug selection involve epigenetic mechanisms

A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.

This is the author accepted manuscript. The final version is available from Nature Publishing Group via http://dx.doi.org/10.1038/ng.3448Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 163,714 directly genotyped, mostly rare, protein-altering variants. Analyzing 16,144 patients and 17,832 controls, we identify 52 independently associated common and rare variants (P < 5 × 10(-8)) distributed across 34 loci. Although wet and dry AMD subtypes exhibit predominantly shared genetics, we identify the first genetic association signal specific to wet AMD, near MMP9 (difference P value = 4.1 × 10(-10)). Very rare coding variants (frequency <0.1%) in CFH, CFI and TIMP3 suggest causal roles for these genes, as does a splice variant in SLC16A8. Our results support the hypothesis that rare coding variants can pinpoint causal genes within known genetic loci and illustrate that applying the approach systematically to detect new loci requires extremely large sample sizes.We thank all participants of all the studies included for enabling this research by their participation in these studies. Computer resources for this project have been provided by the high-performance computing centers of the University of Michigan and the University of Regensburg. Group-specific acknowledgments can be found in the Supplementary Note. The Center for Inherited Diseases Research (CIDR) Program contract number is HHSN268201200008I. This and the main consortium work were predominantly funded by 1X01HG006934-01 to G.R.A. and R01 EY022310 to J.L.H

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Estimating dose—response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and revised Mendelian randomization analyses

Background Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D status is unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) concentrations and risk of coronary heart disease, stroke, and all-cause mortality in observational and Mendelian randomisation frameworks. Methods Observational analyses were undertaken using data from 33 prospective studies comprising 500 962 individuals with no known history of coronary heart disease or stroke at baseline. Mendelian randomisation analyses were performed in four population-based cohort studies (UK Biobank, EPIC-CVD, and two Copenhagen population-based studies) comprising 386 406 middle-aged individuals of European ancestries, including 33 546 people who developed coronary heart disease, 18 166 people who had a stroke, and 27 885 people who died. Primary outcomes were coronary heart disease, defined as fatal ischaemic heart disease (International Classification of Diseases 10th revision code I20-I25) or non-fatal myocardial infarction (I21-I23); stroke, defined as any cerebrovascular disease (I60-I69); and all-cause mortality. Findings Observational analyses suggested inverse associations between incident coronary heart disease, stroke, and all-cause mortality outcomes with 25(OH)D concentration at low 25(OH)D concentrations. In population-wide genetic analyses, there were no associations of genetically predicted 25(OH)D with coronary heart disease (odds ratio [OR] per 10 nmol/L higher genetically-predicted 25(OH)D concentration 0·98, 95% CI 0·95–1·01), stroke (1·01, [0·97–1·05]), or all-cause mortality (0·99, 0·95–1·02). Null findings were also observed in genetic analyses for cause-specific mortality outcomes, and in stratified genetic analyses for all outcomes at all observed levels of 25(OH)D concentrations. Interpretation Stratified Mendelian randomisation analyses suggest a lack of causal relationship for 25(OH)D concentrations with both cardiovascular and mortality outcomes for individuals at all levels of 25(OH)D. Our findings suggest that substantial reductions in mortality and cardiovascular morbidity due to long-term low-dose vitamin D supplementation are unlikely even if targeted at individuals with low vitamin D status